Refining the treatment of advanced nonsmall cell lung cancer

ing the treatment of advanced nonsmall cell lung cancer Review (4603) Total Article Views Authors: Shin Ogita, Antoinette J Wozniak Published Date May 2010 Volume 2010:1(Default) Pages 9 - 22 DOI: http://dx.doi.org/10.2147/LCTT.S6075 Shin Ogita, Antoinette J Wozniak Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA Abstract: Metastatic nonsmall cell lung cancer (NSCLC) is a debilitating and deadly disease with virtually no chance for long-term survival. Chemotherapy has improved both survival and quality of life for patients with advanced disease. Overall survival of patients with metastatic NSCLC has gradually increased from 8 to 12 months over the past three decades with the introduction of new chemotherapeutic drugs and agents directed at novel targets in the cancer cell. Epidermal growth factor receptor and vascular endothelial growth factor are two such targets. Recent developments also include treatment based on histology and the use of maintenance therapy. It has been recognized that lung cancer is a very complex disease. It is common practice to include a number of scientific correlative studies in the design of clinical trials in order to determine predictive markers of benefit from treatment. This article will review the current approach to the treatment of advanced NSCLC including the use of chemotherapy and molecularly targeted agents. Future directions including the use of potentially predictive biomarkers and innovative clinical trials aimed at a more individualized approach to treatment will also be discussed.